ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Neoadjuvant TAR-200 plus cetrelimab improves PCR in muscle-invasive bladder cancer

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer

ESMO 2025: Bladder cancer highlights

ctDNA-guided adjuvant atezolizumab improves OS in MIBC

ESMO 2025: Prostate highlights

ESMO 2025: Renal highlights

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Durvalumab with BCG and maintenance therapy improves disease-free survival in high-risk NMIBC

Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC